Daiichi Sankyo established a Korean branch in 1990 and is celebrating its 30th anniversary this year. It has been continuously growing in the interest and love of doctors for 30 years. Olmesartan Family has firmly maintained its No. 1 M/S in the ARB market by surpassing 110 billion won in 2018, and Lixiana has achieved No. 1 M/S in the NOAC market by surpassing 50 billion won in 2019. In addition, Daiichi Sankyo is providing products that guarantee effectiveness and safety in various areas of the cardiovascular system including nephrology such as Pravastatin Mevalotin, the world’s first statin, and Effient shows outstanding effectiveness in ACS-PCI market.
